Clinical trials: Stage IA Ovarian Cancer
Cancer Survivor, Stage IA Ovarian Epithelial Cancer
Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer
This pilot clinical trial studies survivorship care planning in supporting quality of life in ovarian cancer survivors following primary treatment.
- Conditions
- Cancer Survivor, Stage IA Ovarian Epithelial Cancer, Stage IB Ovarian Epithelial Cancer, Stage IC Ovarian Epithelial Cancer
- Trial name
- NCT02082470
- Testing
- follow-up care, active surveillance, questionnaire administration
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
This randomized phase II trial studies OPT-821 and vaccine therapy to see how well they work compared with OPT-821 alone in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer that has…
- Conditions
- Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer
- Trial name
- NCT00857545
- Testing
- Laboratory Biomarker Analysis, Polyvalent Antigen-KLH Conjugate Vaccine, Saponin-based Immunoadjuvant OBI-821
- Where
- 46 sites in United States
- Volunteers
- 171 people
- Sponsor
- Gynecologic Oncology Group
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Infertility
Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Goserelin may help prevent early menopause in patients undergoing chemotherapy for breast cancer. It is not yet known whether goserelin is effective in preventing early menopause in women undergoing chemotherapy for…
- Conditions
- Breast Cancer, Infertility, Menopausal Symptoms
- Trial name
- NCT00427245
- Testing
- cyclophosphamide, goserelin acetate, adjuvant therapy
- Where
- 66 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- Anglo Celtic Cooperative Oncology Group
Ovarian Cancer, Fallopian Tube Cancer
Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
The purpose of this study is to evaluate giving chemotherapy drugs directly into the abdomen (belly) along with intravenous administration.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
- Trial name
- NCT00582205
- Testing
- Paclitaxel, Cisplatin IP
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Oklahoma
Cervical Cancer, Endometrial Cancer
Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer
RATIONALE: Giving pain medication into the space between the wall of the spinal canal and the covering of the spinal cord or giving it into a vein may help lessen pain caused by cancer surgery.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00295945
- Testing
- fentanyl citrate, hydromorphone hydrochloride, ropivacaine hydrochloride
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- University of California, San Francisco
Ovarian Cancer
PTX-200 and Carboplatin in Ovarian Cancer
The main purpose of this study is to determine if Triciribine (TCN) and carboplatin are safe and tolerable when given together, and to determine if this combination of drugs can help people with recurrent ovarian cancer.
- Trial name
- NCT01690468
- Testing
- Triciribine, Carboplatin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Prescient Therapeutics, Ltd.
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
This study examines at-home monitoring of patient-generated phsyiologic health data and patient-reported outcomes. Patient-generated health data using at-home monitoring devices and smart device applications are used more and…
- Conditions
- Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage I Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04501913
- Testing
- Patient Monitoring, Questionnaire Administration
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- City of Hope Medical Center
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma
Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)
This study aims to assess the safety and tolerability of PHI-101 in patients with platinum-resistance/refractory ovarian, fallopian tubal, and primary peritoneal cancer.
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
- Trial name
- CREATIVE (NCT04678102)
- Testing
- PHI-101 administration
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- Seoul National University Hospital
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT03939481
- Testing
- Chemotherapy, Functional Assessment, Questionnaire Administration
- Where
- 169 sites in United States, Chile and 2 more
- Volunteers
- 1,336 people
- Sponsor
- SWOG Cancer Research Network
Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
This trial studies the chemotherapy toxicity on quality of life in older patients with stage I, stage II, stage III, or stage IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer.
- Conditions
- Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7
- Trial name
- NCT01366183
- Testing
- Assessment of Therapy Complications, Carboplatin, Filgrastim
- Where
- 357 sites in United States
- Volunteers
- 290 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Carcinoma, Stage 0 Fallopian Tube Cancer AJCC v7
Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer
This pilot clinical trial studies how well web-based coping and communication skills intervention works in improving psychological adaptation in patients with gynecological cancer.
- Conditions
- Endometrial Carcinoma, Stage 0 Fallopian Tube Cancer AJCC v7, Stage I Fallopian Tube Cancer AJCC v6 and v7, Stage I Ovarian Cancer AJCC v6 and v7
- Trial name
- NCT03902379
- Testing
- Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Sponsor
- Rutgers, The State University of New Jersey
Fallopian Tube Cancer, Ovarian Cancer
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
RATIONALE: Vaccines made from tumor antigens may help the body build an effective immune response to kill tumor cells. Biological therapies, such as OPT-821, may stimulate the immune system in different ways and stop tumor cells…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00693342
- Testing
- immunological adjuvant OPT-821, polyvalent antigen-KLH conjugate vaccine
- Sponsor
- Gynecologic Oncology Group
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
This longitudinal observational study examines how social health, including social support, social roles, loneliness, social anxiety, and social network characteristics, relates to physical activity, sedentary time, and quality…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT07259304
- Testing
- Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration
- Where
- 3 sites in United States
- Volunteers
- 173 people
- Sponsor
- University of Southern California
Solid Tumor, Breast Cancer
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant…
- Conditions
- Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT05989724
- Testing
- SON-DP
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Qurgen Inc.
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer
This pilot clinical trial studies how well intravital microscopy works in evaluating patients with primary peritoneal, fallopian tube, or stage IA-IV ovarian cancer.
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Stage I Ovarian Cancer, Stage IA Ovarian Cancer
- Trial name
- NCT03297489
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Colon Cancer
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
This is a first-in-man, phase I clinical research study with BKM120, a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor.
- Conditions
- Breast Cancer, Colon Cancer, Ovarian Cancer, Endometrium Cancer
- Trial name
- NCT01068483
- Testing
- BKM120
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen.
- Conditions
- Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- SOFT (NCT00066690)
- Testing
- Exemestane, Laboratory Biomarker Analysis, Oophorectomy
- Where
- 500 sites in United States, Canada and 1 more
- Volunteers
- 3,066 people
- Sponsor
- ETOP IBCSG Partners Foundation
Primary Peritoneal Cavity Cancer, Stage I Endometrial Carcinoma
EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer
This phase II trial is studying how well EF5 works in finding oxygen in tumor cells of patients who are undergoing surgery or biopsy for cervical, endometrial, or ovarian epithelial cancer.
- Conditions
- Primary Peritoneal Cavity Cancer, Stage I Endometrial Carcinoma, Stage I Ovarian Epithelial Cancer, Stage IA Cervical Cancer
- Trial name
- NCT00107445
- Testing
- EF5
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)